| dc.creator | Mennickent C,Sigrid | |
| dc.creator | Bravo D,Marisol | |
| dc.creator | Calvo M,Carlos | |
| dc.creator | Avello L,Marcia | |
| dc.date | 2008-06-01 | |
| dc.date.accessioned | 2017-03-07T16:02:19Z | |
| dc.date.available | 2017-03-07T16:02:19Z | |
| dc.identifier | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000600014 | |
| dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/395023 | |
| dc.description | Results of numerous epidemiologic studies indicate that elevated serum cholesterol, especially the LDL fraction, is a major cause of coronary heart disease (CHD). Epidemiologic and angiographic evidence from primary and secondary prevention studies involving several HMG-CoA reducíase inhibitors (statins) indicate that decreasing elevated serum cholesterol concentration (specifically LDL-cholesterol) can reduce the incidence of CHD and/or progression of atherosclerosis and results in a decrease in associated morbidity and mortality. It has been estimated that each 1% reduction in LDL-cholesterol concentration may result in a 1% decrease in the incidence of CHD. Furthermore, an analysis of pooled data from primary and secondary prevention studies found that treatment with a statin for a median duration of 5.4 years was associated with a 31% and 21% reduction in the risk of major coronary events and total mortality, respectively. This paper deals with the pharmacology of statins, specially with the pleiotropic effects ofthese drugs | |
| dc.format | text/html | |
| dc.language | es | |
| dc.publisher | Sociedad Médica de Santiago | |
| dc.source | Revista médica de Chile v.136 n.6 2008 | |
| dc.subject | Coronary disease | |
| dc.subject | Hydroxymethylglutaryl-CoA reductase inhibitors | |
| dc.subject | Intracellular signalingpeptides and proteins | |
| dc.title | Efectos pleiotrópicos de las estatinas | |
| dc.type | Artículos de revistas | |
